haloperidol has been researched along with Alcohol Drinking in 31 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Recent data indicate that the atypical antipsychotic clozapine, but not the typical antipsychotic haloperidol, decreases alcohol drinking both in patients with schizophrenia and also in the Syrian golden hamster, an animal model of moderate alcohol drinking." | 7.79 | The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. ( Ahmed, J; Chau, DT; Dawson, R; Green, AI; Khokhar, JY; Xie, H, 2013) |
| "We recreated a clozapine-like drug to reduce alcohol drinking in the Syrian golden hamster by combining low dose haloperidol with a norepinephrine α-2 receptor antagonist, idazoxan, and a norepinephrine reuptake inhibitor, desipramine." | 3.81 | Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan. ( Chau, DT; Dawson, R; Green, AI; Khokhar, JY, 2015) |
| " Recent data indicate that the atypical antipsychotic clozapine, but not the typical antipsychotic haloperidol, decreases alcohol drinking both in patients with schizophrenia and also in the Syrian golden hamster, an animal model of moderate alcohol drinking." | 3.79 | The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. ( Ahmed, J; Chau, DT; Dawson, R; Green, AI; Khokhar, JY; Xie, H, 2013) |
| "Remoxipride is a dopamine (DA) D2 antagonist that produces fewer of the side effects normally associated with chronic DA antagonist administration." | 1.30 | Effects of the atypical antipsychotic remoxipride on alcohol self-administration. ( Denning, CE; Files, FJ; Samson, HH, 1998) |
| "Risperidone doses that produce marked 5-HT2, but low dopamine D2, receptor blockade (1 and 0." | 1.29 | 5-HT2 receptor antagonists do not reduce ethanol preference in Sardinian alcohol-preferring (sP) rats. ( Ciccocioppo, R; Massi, M; Panocka, I; Pompei, P, 1993) |
| "The latency of the audiogenic seizures was prolonged by bromocriptine treatment." | 1.29 | Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats. ( Akarsu, ES; Kayaalp, SO; Uzbay, IT, 1994) |
| "Treatment with carbamazepine or phenytoin was effective, but haloperidol increased the severity of the choreoathetoid attacks." | 1.27 | Therapeutic aspects of kinesiogenic paroxysmal choreoathetosis and familial paroxysmal choreoathetosis of the Mount and Reback type. ( Monninger, P; Przuntek, H, 1983) |
| "Nicotine treated rats were not simply seeking calories provided by the EtOH solution, since nicotine treatment did not enhance intake of a distinctively flavored solution isocaloric to 10% ethanol." | 1.27 | Ethanol intake increases during continuous administration of amphetamine and nicotine, but not several other drugs. ( Ellison, G; Nelson, L; Potthoff, AD, 1983) |
| "Most patients with mild withdrawal symptoms do not require hospitalization and respond to non-pharmacologic supportive care." | 1.27 | Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome. ( Naranjo, CA; Sellers, EM, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (29.03) | 18.7374 |
| 1990's | 13 (41.94) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 3 (9.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chau, DT | 3 |
| Khokhar, JY | 2 |
| Dawson, R | 3 |
| Ahmed, J | 1 |
| Xie, H | 1 |
| Green, AI | 3 |
| Rose, L | 1 |
| Burry, L | 1 |
| Mallick, R | 1 |
| Luk, E | 1 |
| Cook, D | 1 |
| Fergusson, D | 1 |
| Dodek, P | 1 |
| Burns, K | 1 |
| Granton, J | 1 |
| Ferguson, N | 1 |
| Devlin, JW | 1 |
| Steinberg, M | 1 |
| Keenan, S | 1 |
| Reynolds, S | 1 |
| Tanios, M | 1 |
| Fowler, RA | 1 |
| Jacka, M | 1 |
| Olafson, K | 1 |
| Skrobik, Y | 1 |
| Mehta, S | 1 |
| Gamaleia, NB | 1 |
| Kuz'mina, TI | 1 |
| Shostak, OA | 1 |
| Gamaleia, AA | 1 |
| Dmitrieva, IG | 1 |
| Keung, WM | 1 |
| Mesholam, RI | 1 |
| Schildkraut, JJ | 1 |
| Overstreet, DH | 1 |
| Knapp, DJ | 1 |
| Breese, GR | 1 |
| Andreas, K | 1 |
| Fischer, HD | 1 |
| Schmidt, J | 1 |
| Fuchs, V | 1 |
| Burbes, E | 1 |
| Coper, H | 1 |
| Przuntek, H | 1 |
| Monninger, P | 1 |
| Potthoff, AD | 1 |
| Ellison, G | 1 |
| Nelson, L | 1 |
| Doenecke, AL | 1 |
| Heuermann, RC | 1 |
| Panocka, I | 3 |
| Ciccocioppo, R | 1 |
| Pompei, P | 2 |
| Massi, M | 3 |
| Uzbay, IT | 1 |
| Akarsu, ES | 1 |
| Kayaalp, SO | 1 |
| Gallant, D | 1 |
| Modell, JG | 2 |
| Mountz, JM | 2 |
| Glaser, FB | 1 |
| Lee, JY | 1 |
| Files, FJ | 1 |
| Denning, CE | 1 |
| Samson, HH | 2 |
| Cohen, C | 1 |
| Perrault, G | 1 |
| Sanger, DJ | 1 |
| Garver, DL | 1 |
| Nair, TR | 1 |
| Christensen, JD | 1 |
| Holcomb, J | 1 |
| Ramberg, J | 1 |
| Kingsbury, S | 1 |
| Salimov, RM | 1 |
| Salimova, NB | 1 |
| Shvets, LN | 1 |
| Maisky, AI | 1 |
| Wilson, AW | 1 |
| Costall, B | 1 |
| Neill, JC | 1 |
| Enggasser, JL | 1 |
| de Wit, H | 1 |
| Amit, Z | 1 |
| Meade, RG | 1 |
| Corcoran, ME | 1 |
| Campbell, AD | 1 |
| Jones, BC | 1 |
| Erwin, VG | 1 |
| Linseman, MA | 1 |
| Naeger, S | 1 |
| Martinez, TT | 1 |
| Naranjo, CA | 1 |
| Sellers, EM | 1 |
| Pfeffer, AO | 1 |
| Kondaurov, VN | 1 |
| Lappo, VG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Daily Sedative Interruption in Critically Ill, Mechanically Ventilated Patients Being Managed With a Sedation Protocol[NCT00675363] | 410 participants (Anticipated) | Interventional | 2008-01-31 | Completed | |||
| Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls[NCT02203786] | Phase 2 | 60 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Risk taking was operationally defined as credits wagered per spin (mean computed for total spins) (NCT02203786)
Timeframe: 1x per test session (total of 4 test sessions) for duration of the study: 4 weeks (1 session/week)
| Intervention | credits/spin on slot machine (Mean) | |
|---|---|---|
| Mean bet under drug | Mean bet under placebo | |
| Fluphenazine - Controls | 14.4 | 12.2 |
| Fluphenazine - Pathological Gamblers | 16.0 | 16.1 |
| Haloperidol - Controls | 11.6 | 9.5 |
| Haloperidol - Pathological Gamblers | 12.8 | 10.4 |
Response time to words (gambling, alcohol, positive affect, negative affect) as a percentage of neutral categorized words (parts of a building). This provides an index of the relative salience of stimuli from these four categories against a baseline of reaction to words with no clinical relevance or emotional valence. Smaller scores indicate faster relative response time to the test stimuli vs. neutral stimuli (i.e., greater salience) (NCT02203786)
Timeframe: At key points during testing: immediately after the slot machine, at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration)
| Intervention | percentage of neutral categorized words (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| post-slots-GAM words under drug | post-slots-ALC words under drug | post-slots POS words under drug | post-slots NEG words under drug | post-slots GAM words under placebo | post-slots ALC words under placebo | post-slots POS words under placebo | post-slots NEG words under placebo | peak AMPH GAM words under drug | peak AMPH ALC words under drug | peak AMPH POS words under drug | peak AMPH NEG words under drug | peak AMPH GAM words under placebo | peak AMPH ALC words under placebo | peak AMPH POS words under placebo | peak AMPH NEG words under placebo | |
| Fluphenazine - Controls | 91.0 | 93.1 | 88.3 | 87.9 | 92.1 | 93.3 | 86.8 | 84.7 | 97.0 | 100.3 | 96.3 | 98.7 | 96.9 | 97.5 | 95.1 | 96.7 |
| Fluphenazine - Pathological Gamblers | 94.0 | 98.1 | 95.3 | 96.5 | 95.0 | 99.0 | 94.9 | 97.2 | 95.8 | 99.5 | 98.7 | 99.4 | 97.9 | 99.9 | 97.7 | 100.0 |
| Haloperidol - Controls | 94.8 | 96.5 | 93.7 | 89.6 | 97.2 | 97.0 | 93.7 | 92.3 | 98.1 | 99.1 | 97.2 | 96.8 | 96.8 | 100.2 | 97.8 | 98.1 |
| Haloperidol - Pathological Gamblers | 91.6 | 95.5 | 91.3 | 89.1 | 91.6 | 94.8 | 92.7 | 93.0 | 96.7 | 101.2 | 98.2 | 99.5 | 95.0 | 99.9 | 98.4 | 99.0 |
Measure changes from baseline, especially physiologic reactivity to the slot machine and amphetamine. (NCT02203786)
Timeframe: At key points in testing: immediately after the slot machine game (change from session baseline), and at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration)(change from session baseline).
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Drug-Change in DBP pre-to-post slot machine | Placebo-Change in DBP pre-to-post slot machine | Drug-Change in DBP pre-amphetamine to peak amph | Placebo-Change in DBP pre-amphetamine to peak amp | |
| Fluphenazine - Controls | 23.6 | 19 | 32.7 | 36.3 |
| Fluphenazine - Pathological Gamblers | 22 | 21.6 | 32.1 | 35.2 |
| Haloperidol - Controls | 15.1 | 19.1 | 28.5 | 26.6 |
| Haloperidol - Pathological Gamblers | 20.2 | 22.5 | 27.2 | 33.6 |
Number of individual spins in a 15-minute slot machine game. Each spin corresponds to one wager. (NCT02203786)
Timeframe: 15-minutes
| Intervention | individual spins/15-minutes (Mean) | |
|---|---|---|
| Spins/15-minutes under Drug | Spins/15-minutes under Placebo | |
| Fluphenazine - Controls | 71.8 | 66.7 |
| Fluphenazine - Pathological Gamblers | 78.5 | 68.4 |
| Haloperidol - Controls | 66.4 | 72.2 |
| Haloperidol - Pathological Gamblers | 76.9 | 88.6 |
Self-reported Confidence to Refrain from Gambling (0 - 10) was assessed at test session baseline, before the slot machine and after the slot machine (Phase 1); and before amphetamine and at peak amphetamine (Phase 2). The maximum score (10) denotes complete confidence to refrain from gambling (i.e., NO urge or compulsion to gamble); the minimum score (0) denotes complete lack of confidence to refrain from gambling (i.e., overwhelming urge to gamble). Scores between 10 and 0 denote intermediate confidence to refrain from gambling with LOWER scores denoting less confidence to refrain from gambling -- i.e., GREATER urge or compulsive motivation to gamble. Scores shown are based on single item visual analogue ratings 0-10 from each participant at the specified time point. The mean (SD) of these single item ratings is presented for each sub-group. (NCT02203786)
Timeframe: At key points in testing: immediately after the slot machine game, and at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration).
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Drug - Confidence not to gamble after slot machine | Placebo - Confidence not to gamble after slot mach | Drug - Confidence not to gamble at peak amphetamin | Plac -Confidence not to gamble at peak amphetamine | |
| Fluphenazine - Controls | 9.3 | 8.2 | 9.8 | 9.3 |
| Fluphenazine - Pathological Gamblers | 4.8 | 4.8 | 6.4 | 5.7 |
| Haloperidol - Controls | 9.5 | 9 | 9.8 | 9.4 |
| Haloperidol - Pathological Gamblers | 4.8 | 4.2 | 5.2 | 5.5 |
Credits (NCT02203786)
Timeframe: 15-minutes
| Intervention | credits (Mean) | |
|---|---|---|
| Winnings (Final Credit Tally) under drug | Winnings (Final Credit Tally) under Placebo | |
| Fluphenazine - Controls | 544.3 | 215 |
| Fluphenazine - Pathological Gamblers | 277.8 | 140.8 |
| Haloperidol - Controls | 449.1 | 339.2 |
| Haloperidol - Pathological Gamblers | 239 | 562.4 |
1 review available for haloperidol and Alcohol Drinking
| Article | Year |
|---|---|
The lateral hypothalamus, catecholamines and ethanol self-administration in rats.
Topics: Alcohol Drinking; Aldehydes; Animals; Catecholamines; Cyanides; Disulfiram; Dopamine beta-Hydroxylas | 1975 |
4 trials available for haloperidol and Alcohol Drinking
| Article | Year |
|---|---|
Prevalence, risk factors, and outcomes associated with physical restraint use in mechanically ventilated adults.
Topics: Adult; Aged; Alcohol Drinking; Analgesics, Opioid; Antipsychotic Agents; Benzodiazepines; Clinical P | 2016 |
Effect of haloperidol on measures of craving and impaired control in alcoholic subjects.
Topics: Adult; Alcohol Drinking; Alcohol Withdrawal Delirium; Alcoholism; Basal Ganglia; Corpus Striatum; Do | 1993 |
Atrophic and static (neurodevelopmental) schizophrenic psychoses: premorbid functioning, symptoms and neuroleptic response.
Topics: Adult; Aging; Alcohol Drinking; Algorithms; Antipsychotic Agents; Atrophy; Brain; Cerebral Ventricle | 1999 |
Haloperidol reduces stimulant and reinforcing effects of ethanol in social drinkers.
Topics: Adult; Affect; Alcohol Drinking; Beverages; Choice Behavior; Dopamine Antagonists; Double-Blind Meth | 2001 |
26 other studies available for haloperidol and Alcohol Drinking
| Article | Year |
|---|---|
The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat.
Topics: Alcohol Drinking; Alcoholism; Animals; Antipsychotic Agents; Body Weight; Clozapine; Dose-Response R | 2013 |
Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Adult; Alcohol Drinking; Anim | 2015 |
[Method for determining dopamine and morphine binding sites in lymphocytes from human peripheral blood].
Topics: Alcohol Drinking; Binding Sites; Dopamine; Dopamine Antagonists; Ethanol; Haloperidol; Histocytochem | 2003 |
Clozapine reduces alcohol drinking in Syrian golden hamsters.
Topics: Alcohol Drinking; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cricetinae; Haloperido | 2004 |
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.
Topics: Alcohol Drinking; Aminopyridines; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiaz | 2007 |
[Effect of central effective substances on alcohol preference].
Topics: Alcohol Drinking; Alcoholism; Animals; Arecoline; Atropine; Central Nervous System Stimulants; Cypro | 1983 |
The influence of haloperidol and aminooxyacetic acid on etonitazene, alcohol, diazepam and barbital consumption.
Topics: Acetates; Alcohol Drinking; Aminooxyacetic Acid; Animals; Barbital; Barbiturates; Benzimidazoles; Br | 1984 |
Therapeutic aspects of kinesiogenic paroxysmal choreoathetosis and familial paroxysmal choreoathetosis of the Mount and Reback type.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Athetosis; Carbamazepine; Child; Chorea; Female; Haloperi | 1983 |
Ethanol intake increases during continuous administration of amphetamine and nicotine, but not several other drugs.
Topics: Alcohol Drinking; Amphetamine; Animals; Caffeine; Drinking Behavior; Drug Implants; Female; Haloperi | 1983 |
Treatment of haloperidol abuse with diphenhydramine.
Topics: Adolescent; Adult; Alcohol Drinking; Diazepam; Diphenhydramine; Female; Haloperidol; Humans; Male; S | 1980 |
5-HT2 receptor antagonists do not reduce ethanol preference in Sardinian alcohol-preferring (sP) rats.
Topics: Alcohol Drinking; Animals; Antipsychotic Agents; Haloperidol; Isoxazoles; Male; Piperidines; Rats; R | 1993 |
Suppression of alcohol preference in rats induced by risperidone, a serotonin 5-HT2 and dopamine D2 receptor antagonist.
Topics: Alcohol Drinking; Animals; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Haloperidol; Isox | 1993 |
Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats.
Topics: Acoustic Stimulation; Alcohol Drinking; Animals; Behavior, Animal; Bromocriptine; Dopamine; Ethanol; | 1994 |
Ethical considerations of alcohol administration in human research studies.
Topics: Alcohol Drinking; Alcoholism; Behavioral Research; Dose-Response Relationship, Drug; Ethical Review; | 1993 |
Effects of the atypical antipsychotic remoxipride on alcohol self-administration.
Topics: Alcohol Drinking; Animals; Antipsychotic Agents; Central Nervous System Depressants; Conditioning, O | 1998 |
Preferential involvement of D3 versus D2 dopamine receptors in the effects of dopamine receptor ligands on oral ethanol self-administration in rats.
Topics: Alcohol Drinking; Animals; Conditioning, Operant; Dopamine Agents; Dopamine Agonists; Dopamine Antag | 1998 |
Haloperidol administered subchronically reduces the alcohol-deprivation effect in mice.
Topics: Alcohol Drinking; Animals; Central Nervous System Depressants; Dopamine Antagonists; Ethanol; Explor | 2000 |
Manipulation of operant responding for an ethanol-paired conditioned stimulus in the rat by pharmacological alteration of the serotonergic system.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Alcohol Drinking; Amphetamines; Animals; Buspirone; Conditio | 2000 |
Long-lasting suppression of alcohol preference in rats following serotonin receptor blockade by ritanserin.
Topics: Alcohol Drinking; Animals; Depression, Chemical; Fenclonine; Haloperidol; Male; Rats; Rats, Inbred S | 1992 |
Effect of haloperidol on craving and impaired control following alcohol consumption in alcoholic subjects.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle | 1992 |
Regional characterization of brain neurotensin receptor subtypes in LS and SS mice.
Topics: Alcohol Drinking; Animals; Binding, Competitive; Brain; Chlorpheniramine; Haloperidol; Histamine H1 | 1991 |
Effects of dopaminergic agents on alcohol consumption by rats in a limited access paradigm.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Alcohol Drinking; Amphetamine; Animals; | 1990 |
The effect of tetrahydropapaveroline, bromocriptine, haloperidol, and lithium on voluntary ethanol ingestion.
Topics: Alcohol Drinking; Animals; Bromocriptine; Dopamine; Haloperidol; Lithium; Rats; Rats, Inbred Strains | 1990 |
Clinical assessment and pharmacotherapy of the alcohol withdrawal syndrome.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; Anti-Anxiety Agents; Benzodiazepines; Chl | 1986 |
Haloperidol and apomorphine effects on ethanol reinforcement in free feeding rats.
Topics: Alcohol Drinking; Animals; Apomorphine; Dopamine; Haloperidol; Male; Rats; Reinforcement, Psychology | 1988 |
[Methods of assessing the toxic properties of polymeric filling materials (author's transl)].
Topics: Alcohol Drinking; Animals; Body Weight; Cell Count; Eosinophils; Epoxy Resins; Guinea Pigs; Histamin | 1978 |